Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | SVP, Bus Dev, General Counsel | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,078 |
Last balance in matching sequence
After 2026-01-09 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-01-09 · Grant · Acquired 15,000 · Balance 39,579 F1: Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2: Includes 17,750 unvested restricted stock. Row 2 · 2026-01-09 · Tax withholding · Disposed 1,401 · Balance 38,178 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 17,750 unvested restricted stock. Row 3 · 2026-01-09 · Tax withholding · Disposed 840 · Balance 37,338 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 17,750 unvested restricted stock. Row 4 · 2026-01-09 · Tax withholding · Disposed 747 · Balance 36,591 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 17,750 unvested restricted stock. Row 5 · 2026-01-09 · Tax withholding · Disposed 513 · Balance 36,078 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 17,750 unvested restricted stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-01-09 | Direct | 7,000 |
Reported balance
After 2026-01-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-09 · Grant · Acquired 7,000 · Balance 7,000 F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
F2: Includes 17,750 unvested restricted stock.
F3: Shares withheld as payment of a tax liability on vesting of restricted stock.
F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · derivative · entry 6 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-01-09 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 513 | $1.97 | $1,010.61 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · nonDerivative · entry 5 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,078 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 17,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 747 | $1.97 | $1,471.59 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · nonDerivative · entry 4 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,591 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 17,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 840 | $1.97 | $1,654.80 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · nonDerivative · entry 3 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,338 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 17,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 1,401 | $1.97 | $2,759.97 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · nonDerivative · entry 2 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,178 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 17,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002055011-26-000003 · wk-form4_1768338486.xml · nonDerivative · entry 1 Imam Tariq · CIK 0002055011 · SVP, Bus Dev, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,579 F1 · shares: Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 17,750 unvested restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.